Results 91 to 100 of about 61,821 (357)

New simplified molecular design for functional T cell receptor [PDF]

, 1993
We have produced a chimeric single-chain T cell receptor (TcR) that combines the specific antibody recognition function and TcR/CD3 signaling properties within the same polypeptide chain.
Clevers, Cosson, Eshhar, Frank, Gillis, Gunning, Hackett, Huston, Ihle, Irving, Lanzavecchia, Leo, Mosmann, Oi, Romeo, Sterz, Tada, Traunecker, Walker, Wegener, Weissman, Weissman, White, Zamoyska   +23 more
core   +1 more source

Bispecific Antibody 4G7xH22 [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma: a retrospective real-world study

Frontiers in Immunology
BackgroundAt the time of diagnosis, 80% of patients with pancreatic ductal adenocarcinoma (PDAC) are already at an unresectable advanced stage. The median overall survival (mOS) with traditional AG chemotherapy is only 8.5 months. The bispecific antibody
Wenke Qin, Yan Du, Xuean Zhao, Yongqing Zhao, Yan Zhang, Shuze Zhang, Zengxi Yang, Xin Li, Jubao Niu, Dewen Zhao, Kongyuan Wei, Hui Zhang, Hui Zhang   +12 more
doaj   +1 more source

Entwicklung eines Inkubationssystems für ein inverses Mikroskop zur Langzeitbeobachtung von Zellkulturen in gekammerten Objektträgern [PDF]

, 2001
Trifunctional bispecific antibodies open up new immunological possibilities in tumour treatment. Prior to clinical application, comprehensive investigations using animal models and in vitro examinations need to be done.
A. Buchner, Lindhofer H., R. Riesenberg, Riesenberg R., W. Feicht, Zeidler R.   +5 more
core   +1 more source

Constraint of Lignin–Carbohydrate Complex Orchestrated on Polyphenol in Oil–Water Interface Targeting Ulcerative Colitis Therapy

Advanced Science, EarlyView.
This study constructed the W1/O/W2 emulsion–based targeted therapy delivery system for ulcerative colitis (UC) utilizing LCC as surfactant for the first time. This multifunctional emulsion offered certain therapeutic advantages for UC, including targeted colonic delivery of active compounds, synergistic modulation of gut microbiota through combined ...
Qian Wu, Xingyu Zhang, Jingjia Zhang, Gaohui Huang, Chen Zhou, Chunlin Li, Xiaojun Huang, Jianbo Xiao, Nianjie Feng, Yuanbin She   +9 more
wiley   +1 more source

Supplementary Fig. S5 from Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design [PDF]

, 2023
Nam-Kyung Lee, Yang Su, Scott Bidlingmaier, Bin Liu   +3 more
openalex   +1 more source

Copper Depletion Nanoparticles Potentiate Cancer Immunotherapy by Avoiding Innate and Adaptive Immune Resistance

Advanced Science, EarlyView.
A mitochondria‐targeted copper depletion nanoplatform (CYN‐CDA@Alb) was developed to selectively disrupt tumor mitochondria copper, which then reprogrammed the tumor immune microenvironment by depressing PD‐L1 and CD47 expression simultaneously. By doing this, CYN‐CDA@Alb reversed radiotherapy‐induced immune tolerance, showing the potential usage of ...
Zaigang Zhou, Ke Li, Xuelan Li, Lei Yi, Zhengxiang Wang, Huan Ding, Sheng Wu, Feiyu Liu, Yuan Li, Rui Cheng, Jianliang Shen   +10 more
wiley   +1 more source

Elranatamab in Heavily Pretreated Triple-class Refractory Multiple Myeloma: A Single-center Experience

Acta Haematologica Oncologica Turcica
Aim: This study aimed to assess the real-world performance of elranatamab in terms of its effectiveness, safety, and tolerability among patients diagnosed with triple-class refractory-multiple myeloma (TCR-MM) who have undergone extensive prior treatment.
Ant Uzay
doaj   +1 more source

Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer [PDF]

, 2017
Background: One bottleneck for adoptive T cell therapy (ACT) is recruitment of T cells into tumors. We hypothesized that combining tumor-specific T cells, modified with a marker antigen and a bispecific antibody (BiAb) that selectively recognizes ...
Abken, Hinrich, Bourquin, Carole, Castoldi, Raffaella, Chaloupka, Michael, Chmielewski, Markus, Endres, Stefan, Grassmann, Simon, Henkel, Jonas, Klein, Christian, Kobold, Sebastian, Niederfellner, Gerhard, Rothenfußer, Simon, Schendel, Dolores J., Schmollinger, Jan C., Schnurr, Max, Steffen, Julius, Sustmann, Claudio, Zeng, Yi   +17 more
core